Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Inclusion Criteria

• •Clinically stable Type 2 Diabetes Mellitus
• •Females without childbearing potential
• •Body mass index (BMI) \>= 18.5 kg/m2 and \<= 39.9 kg/m2
• •Hemoglobin A1c levels \>= 6.5% and \<= 10%
• •Fasting blood glucose levels \>= 140 mg/dL and \<= 270 mg/dL
• •Systolic blood pressure \>= 95 mmHg and \<= 160 mmHg, and diastolic blood pressure \>= 50 mmHg and \<= 100 mmHg, and pulse rate \>= 50 bpm
• •Patients who have not been administered anti-diabetic medication within 2 weeks Prior to dosing
• •Medicines if necessary for Hypertension or Dyslipidemia should be administered with stable dosage at least 3 months
• •Treatment with diet and exercise should be unchanged for more than 3 months